The Pancreatic Ductal Adenocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Ductal Adenocarcinoma Market.

Some of the key takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Pancreatic Ductal Adenocarcinoma treatment therapies with a considerable amount of success over the years. 
• Pancreatic Ductal Adenocarcinoma companies working in the treatment market are Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, Panbela Therapeutics, Cantargia, Arcus Biosciences, and others, are developing therapies for the Pancreatic Ductal Adenocarcinoma treatment 

• Emerging Pancreatic Ductal Adenocarcinoma therapies in the different phases of clinical trials are- DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, SBP 101, Nadunolimab, Zimberelimab, and others are expected to have a significant impact on the Pancreatic Ductal Adenocarcinoma market in the coming years.   
• In July 2022, Cend Therapeutics, Inc. announced that The Lancet Gastroenterology and Hepatology published data from the Phase 1b study of CEND-1, Cend’s lead investigational drug, in combination with gemcitabine and nab-paclitaxel for the treatment of first-line, metastatic pancreatic ductal adenocarcinoma (“mPDAC”).
• In July 2022, I-Mab announced that the first patient in China has been treated with TJ-CD4B (also known as ABL111), a novel Claudin 18.2 x 4-1BB bispecific antibody, in a Phase 1 international multi-center clinical trial (IMCT) for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma, and pancreatic ductal carcinoma.
• In June 2022, BioNTech SE announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability of the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) autogene cevumeran (also known as BNT122, RO7198457) in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC). Feasibility of the process of profiling each patient’s tumor to inform individualized vaccine design and on-demand manufacturing of iNeST in a clinically relevant timeframe was confirmed. The preliminary results showed a favorable safety profile as well as encouraging signs of clinical activity.
• In June 2022, BioLineRx Ltd. announced that the Company had entered into a collaboration agreement with GenFleet Therapeutics, an immuno-oncology-focused biopharmaceutical company based in China, to advance Motixafortide through a randomized Phase 2b clinical trial in pancreatic ductal adenocarcinoma, or PDAC.
• In May 2022, Elicio Therapeutics, announced that it had entered into a clinical supply agreement with Regeneron to evaluate the safety and efficacy of Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron’s Libtayo® (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in patients with KRAS-driven tumors. The combination therapy will be studied in KRAS-driven tumors, including Stage III and IV non-small cell lung cancer (NSCLC), Stage IV colorectal cancer (CRC), and unresectable, locally advanced, or oligometastatic pancreatic ductal adenocarcinoma (PDAC).
• In May 2022, OSE Immunotherapeutics SA and its clinical partners GERCOR, ARCAGY-GINECO, and the FoRT Foundation (Fondazione Ricerca Traslazionale), announced four poster presentations featuring neoepitope combination Tedopi® in various cancer indications at the American Society of Clinical Oncology (ASCO) Annual Meeting that was held from June 4 – 7, 2022 in Chicago. The first poster was titled, “A randomized non-comparative phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo), or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): first interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY”.
• In May 2022, Purple Biotech Ltd. announced the initiation of the Phase 2 portion of its ongoing study of CM24, a first-in-class monoclonal antibody with the potential to treat multiple cancers. Phase 2 is an open-label, multicenter study in subjects with metastatic pancreatic cancer (PDAC) to evaluate the safety and tolerability of CM24 in combination with the PD-1 inhibitor Opdivo® (nivolumab) and chemotherapy. The primary study endpoint is to evaluate preliminary efficacy in 2nd line PDAC.
• In March 2022, Alligator Bioscience announced an update on the ongoing OPTIMIZE-1 clinical Phase Ib/II trial in first-line metastatic pancreatic cancer with the company’s lead asset, mitazalimab. Safety evaluation of the second dose-escalation cohort (900 µg/kg of mitazalimab in combination with mFOLFIRINOX) has concluded, which marks the successful completion of the Phase Ib part of the study. The Data Review Committee had declared the 900 µg/kg mitazalimab dose to be safe and recommended that the dosing level should be continued for the Phase II study. Enrollment for Phase II has begun and is ongoing at sites in Europe. OPTIMIZE-1, an open-label, multi-center Phase Ib/II study is assessing the safety and efficacy of mitazalimab in combination with chemotherapy, mFOLFIRINOX, in patients with metastatic pancreatic ductal adenocarcinoma.

Pancreatic Ductal Adenocarcinoma Overview

Due to delayed diagnosis and a poor prognosis, pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive, fatal cancer. More than 90% of cases of pancreatic cancer are caused by this form of tumor, which is the most common type and develops in the exocrine compartment.

Get a Free Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight

Emerging Pancreatic Ductal Adenocarcinoma Drugs Under Different Phases of Clinical Development Include:

• DCC-3116: Deciphera Pharmaceuticals
• RMC-6236: Revolution Medicines
• SX-682: Syntrix Biosystems
• AMP 945: Amplia Therapeutics
• ZB131: ZielBio
• CEND-1: Cend Therapeutics Inc
• Onvansertib: Cardiff Oncology
• YH003: Eucure Biopharma
• KN046: Jiangsu Alphamab Biopharmaceuticals
• SBP 101: Panbela Therapeutics
• Nadunolimab: Cantargia
• Zimberelimab: Arcus Biosciences

Pancreatic Ductal Adenocarcinoma Route of Administration

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

Pancreatic Ductal Adenocarcinoma Molecule Type

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types, such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment

• Pancreatic Ductal Adenocarcinoma Assessment by Product Type
• Pancreatic Ductal Adenocarcinoma By Stage and Product Type
• Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
• Pancreatic Ductal Adenocarcinoma By Stage and Route of Administration
• Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
• Pancreatic Ductal Adenocarcinoma by Stage and Molecule Type

DelveInsight’s Pancreatic Ductal Adenocarcinoma Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pancreatic Ductal Adenocarcinoma product details are provided in the report. Download the Pancreatic Ductal Adenocarcinoma pipeline report to learn more about the emerging Pancreatic Ductal Adenocarcinoma therapies

Some of the key companies in the Pancreatic Ductal Adenocarcinoma Therapeutics Market include:

Key companies developing therapies for Pancreatic Ductal Adenocarcinoma are – Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.

Pancreatic Ductal Adenocarcinoma Pipeline Analysis:

The Pancreatic Ductal Adenocarcinoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma Treatment.
• Pancreatic Ductal Adenocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pancreatic Ductal Adenocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma drugs and therapies

Pancreatic Ductal Adenocarcinoma Pipeline Market Drivers

• Increasing pervasiveness of the disease, increasing demand of targeted therapy are some of the important factors that are fueling the Pancreatic Ductal Adenocarcinoma Market.

Pancreatic Ductal Adenocarcinoma Pipeline Market Barriers

• However, lack of early diagnostic markers, complicated and multifactorial nature of disease • Diverse genetics and rapid metastasis and other factors are creating obstacles in the Pancreatic Ductal Adenocarcinoma Market growth.

Scope of Pancreatic Ductal Adenocarcinoma Pipeline Drug Insight    

• Coverage: Global
• Key Pancreatic Ductal Adenocarcinoma Companies: Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, Panbela Therapeutics, Cantargia, Arcus Biosciences, and others
• Key Pancreatic Ductal Adenocarcinoma Therapies: DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, SBP 101, Nadunolimab, Zimberelimab, and others
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment: Pancreatic Ductal Adenocarcinoma current marketed and Pancreatic Ductal Adenocarcinoma emerging therapies
• Pancreatic Ductal Adenocarcinoma Market Dynamics: Pancreatic Ductal Adenocarcinoma market drivers and Pancreatic Ductal Adenocarcinoma market barriers 

Request for Sample PDF Report for Pancreatic Ductal Adenocarcinoma Pipeline Assessment and clinical trials

Table of Contents

1. Pancreatic Ductal Adenocarcinoma Report Introduction

2. Pancreatic Ductal Adenocarcinoma Executive Summary

3. Pancreatic Ductal Adenocarcinoma Overview

4. Pancreatic Ductal Adenocarcinoma- Analytical Perspective In-depth Commercial Assessment

5. Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics

6. Pancreatic Ductal Adenocarcinoma Late Stage Products (Phase II/III)

7. Pancreatic Ductal Adenocarcinoma Mid Stage Products (Phase II)

8. Pancreatic Ductal Adenocarcinoma Early Stage Products (Phase I)

9. Pancreatic Ductal Adenocarcinoma Preclinical Stage Products

10. Pancreatic Ductal Adenocarcinoma Therapeutics Assessment

11. Pancreatic Ductal Adenocarcinoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pancreatic Ductal Adenocarcinoma Key Companies

14. Pancreatic Ductal Adenocarcinoma Key Products

15. Pancreatic Ductal Adenocarcinoma Unmet Needs

16 . Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers

17. Pancreatic Ductal Adenocarcinoma Future Perspectives and Conclusion

18. Pancreatic Ductal Adenocarcinoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services